Indicators of immune activation in depressed patients

Advances in Experimental Medicine and Biology

Volumn 461, Issue , 1999, Pages 59-73

  Sluzewska, A ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 2 GLOBULIN; ALPHA GLOBULIN; ANTIBODY; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; CYTOKINE; GANGLIOSIDE; IMMUNOGLOBULIN; OROSOMUCOID; PROTEIN; SEROTONIN;

ACUTE PHASE RESPONSE; CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DEPRESSION; ELECTROPHORESIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; INFLAMMATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T LYMPHOCYTE ACTIVATION;

EID: 0033282758     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-585-37970-8_4     Document Type: Conference Paper

References (121)

1. Purification and properties of human plasma endogenous modulator for platelet tricyclic binding/serotonine transport complex
2. The dexamethasone suppression test as a predictor of antidepressant response
3. Borna disease virus: A possible etiologic factor in human affective disorders?
4. Assessment of adrenocortical activity in refractory depression: Steroid suppression with ketoconazole
5. The cytokine network
6. Cytokines in health and disease
7. Interaction among hepatocyte-stimulating factors, interleukin 1, and glucocorticoids for regulation of acute phase proteins in human hepatoma (Hep G2) cells
8. The syntax of immune-neuroendocrine communication
9. Borna disease virus-specific antibodies in patients with HIV infection and with mental disorders
10. First isolation of infectious human Borna disease virus from patients with mood disorders
11. Affinity electrophoresis for diagnosis of cancer and inflammatory conditions
12. Cytokine involvement in central nervous system disease: Implications from transgenic mices
13. Antibody and cell-mediated immunity to herpes simplex virus in psychotic depression
14. Urinary free cortisol excretion in depression
15. Biological significance of soluble IL-2 receptor
16. Cytokines and autoimmunity
17. Cortisol and treatment of depression: Predictive value of spontaneous and suppressed cortisol levels and course of spontaneous plasma cortisol
18. The concepts of stress and stress system disorders: Overview of physical and behavioural homeostasis
19. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation
20. Natural antibodies might prevent autoimmune disease
21. Inhibition of platelet aggregation by native and disialised alpha-1-acid glycoprotein
22. Interleukin-1, tumor necrosis factor, and their specific inhibitors
23. The biological properties of interleukin-1
24. Learning deficiencies in Borna disease virus-infected but clinicaly healthy rats
25. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction
26. Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression but not with schizophrenia
27. Glycan variations of human alpha-1-acid glycoprotein modulate the biology of macrophages
28. Progress in treatment-resistant and treatment refractory depression: We still have a long way to go
29. Gangliosides as cell surface receptors and transducers of biological signals
30. Effects of recombinant human interleukin-1 alpha,-1 beta, 2, and 6 on ACTH synthesis and release in the mouse pituitary tumor cell line AtT-20
31. Autoantibodies in affective disorders
32. Stress, loneliness and changes in herpes virus latency
33. Psychiatric implications of basic and clinical studies with corticotropin-relasing factor
34. Editorial: Stress system abnormalities in melancholic and atypical depression: Molecular, pathophysiological, and therapeutic implications
35. Borna disease - Neuropathology and pathogenesis
36. Alpha-1-acid glycoprotein in major depressives and eating disorders
37. Review article: Interleukin-6 and the acute phase response
38. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression
39. Clinical and biological correlantes of treatment-resistant depression: An overview
40. Reduction of immune function in life stress and depression
41. Elevated levels of acute phase plasma proteins in major depression
42. Sickness behavior as a new target for drug development
43. Increased alpha-1-acid glycoprotein in depression lowers free fraction of imipramine
44. Drug binding to human alpha-1-acid glycoprotein in health and disease
45. Neuronal reactivation of herpes simplex virus may involve interleukin-6
46. Lymphocyte mitogenesis, immunoglobulin and component levels in depressed patients and normal controls
47. The acute phase response: An overview
48. The effect of psychological stress on plasma interleukin-6 activity in rats
49. Elevated levels of prostaglandin E2 and tromboxane B2 in depression
50. Elevated in vivo and in vitro secretion of CD8-alpha molecules in patients with systemic lupus erythematosus
51. A serological study on mentally ill patients with particular reference to prevalence of herpes virus infections
52. Determination of lectin-sugar dissociation constants by agarose affinity electrophoresis
53. Microheterogeneity forms of alpha-1-acid glycoprotein as indicator of rheumatoid arthritis activity
54. The impaired mitogen lymphocyte stimulation in severely depressed patients: A complex interface between HPA-axis hyperfunction, noradrenergic activity, and ageing process
55. Antiphospholipid, antinuclear, Ebstein-Barr and cytomegalovirus antibodies, and soluble interleukin-2 receptor in depressive patients
56. Higher alpha-1-antitrypsin, haptoglobin, ceruloplasmin, and lower retinol protein plasma levels during depression. Further evidence for the existence of an inflammatory process during that illness
57. Disturbances in acute phase proteins during melancholia: Additional evidence for presence of inflammatory process during that illness
58. Leukocytosis, monocytosis and neutrophilia: Hallmarks of severe depression
59. Acute phase protein alterations in major depression: A review
60. Multiple reciprocal relationships between in vivo cellular immunity and hypothalamic-pituitary-adrenal axis in depression
61. Increased neopterin and interferon secretion and lower availability of L-tryptophan in major depression; further evidence for activation of cell-mediated immunity
62. Increased plasma levels of interleukin-6, soluble interleukin-2, and transferrin receptors in major depression
63. Total serum protein and serum protein fractions in depression: Relationships to depressive symptoms and glucocorticoid activity
64. Immunoendocrine aspects of major depression
65. The acute phase protein response in schizophrenia, mania, and major depression: Effects of psychotropic drugs
66. Poor response to antidepressants and dexamethasone nonsuppression
67. Investigations of the cellular immunity during depression and the free interval: Evidence for immune activation in affective psychosis
68. Response to steroid suppression in major depression resistant to antidepressant therapy
69. Interleukin-1 stimulates the secretion of adrenocorticotropic hormone in conscious freely-moving rats
70. Interleukin-1 and interleukin-6 stimulate the release of corticotropin-releasing hormone from rat hypothalamus in vitro via the ecosanoid cyclooxygenase pathway
71. Elevated plasma concentration of alpha-1-acid glycoprotein, a putative endogenous inhibitor of tritiated imipramine binding site in depressed patients
72. The corticotropin-releasing factor (CRF) hypothesis of depression: New findings and new directions
73. Increased soluble interleukin-2 receptor concentration in suicide attempters
74. Lymphocyte responses and cytokines
75. Microheterogeneity of alpha-1-acid glycoprotein in detection of intercurrent infection in rheumatoid arthritis
76. Glycosylation of four acute-phase glycoproteins secreted by rat liver cells in vivo and in vitro. Effects of inflammation and dexamethasone
77. Changes in the serum concentration and glycosylation of human alpha-1-acid glycoprotein and alpha-1protease inhibitor in severely burned patients: Relation to interleukin-6 levels
78. Progress in plasma proteins
79. Alpha, beta, gamma omega- the structure of plasma proteins
80. Serum protein electrophoresis and total serum proteins
81. Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders
82. Lymphocyte function in major depressive disorder
83. Antibodies against serotonin and gangliosides in schizophrenia and major depressive disorder
84. No antibody binding to serotonin in serum of patients with paranoid schizophrenia and major depressive disorder
85. Cortisol levels and immunological indices in depression
86. Haptoglobin levels in chronic mild stress model of depression in rats before and after treatment
87. The effect of lithium, carbamazepine and fluoxetine on alpha-1-acid glycoprotein, and alpha-1-antichymotripsin in depressed patients
88. The effect of short-term treatment with lithium and carbamazepine on some immunological indices in depressed patients
89. Interleukin-6 levels in depressed patients before and after treatment with fluoxetine
90. Increased levels of alpha-1-acid glycoprotein and interleukin-6 in refractory depression
91. The effects of treatment with lithium and carbamazepine on some interleukin and their receptors in depressed patients
92. Changes in acute phase proteins in depressed patients during treatment with fluoxetine and venlafaxine
93. Concentration and microheterogeneity glycophorms of alpha-1-acid glycoprotein in major depression
94. Indicators of immune activation in major depression
95. Immune activation in endogenous depression
96. Acute phase proteins in chronic mild model of depression
97. Changes in concentration and microheterogeneity of two acute phase proteins in major depression
98. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression
99. Total serum protein and serum protein fractions in major depression and treatment resistant depression
100. Relationships between selected immunological parameters and cortisol in treatment resistant depression
101. Serum antibodies in relation to immune activation in major depression
102. Changes in plasma proteins in depressed patients and rodent model of depression
103. Changes in immunoglobulines, component and acute phase proteins levels in depressed patients and normal controls
104. An acute phase protein response in the olfactory bulbectomised rat: Effect of sertraline treatment
105. Herpes simplex virus encephalitis of the human adult: Reactivation of latent brain infection
106. Albumin decrement in depression and cholesterol decrement in mania
107. Treatment-resistant depression
108. Prostaglandin-dependent in vitro stimulation of adrenocortical steroidogenesis by interleukins
109. Soluble CD8 during T cell activation
110. N-glycosylation of serum proteins in disease and its investigation using lectins
111. Control of glycosylation alterations of acute phase proteins
112. Changes in glycosylation of acute phase proteins in health and disease: Occurence regulation and function
113. Lower total serum protein, albumin, and globulin in major and treatment resistant depression: Effects of antidepressant treatment
114. Effects of alpha-1-acid glycoprotein on human polynuclear neutrophils: Influence of glycan microheterogeneity
115. Antihistone antibodies in schizophrenia and affective disorders
116. A soluble form of the human transferrin receptor is released by activated lymphocytes in vitro
117. Interleukin-6: Historical background, genetics, and biological significance
118. Exposure to physical and psychological stressors elevates plasma interleukin-6: Relationships to the activation of hypothalamic-pituitary-adrenal axis
119. Major depression, viral reactivation and immune system